MC2260A1 - Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation - Google Patents

Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation

Info

Publication number
MC2260A1
MC2260A1 MC912192A MC2192A MC2260A1 MC 2260 A1 MC2260 A1 MC 2260A1 MC 912192 A MC912192 A MC 912192A MC 2192 A MC2192 A MC 2192A MC 2260 A1 MC2260 A1 MC 2260A1
Authority
MC
Monaco
Prior art keywords
acid
ligand
process according
solution
divalent metal
Prior art date
Application number
MC912192A
Other languages
English (en)
French (fr)
Inventor
Simon Jaime
R Garlich Joseph
Keith R
Mcmillan Kenneth
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of MC2260A1 publication Critical patent/MC2260A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
MC912192A 1990-06-18 1991-06-11 Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation MC2260A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53887190A 1990-06-18 1990-06-18

Publications (1)

Publication Number Publication Date
MC2260A1 true MC2260A1 (fr) 1993-04-26

Family

ID=24148781

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912192A MC2260A1 (fr) 1990-06-18 1991-06-11 Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation

Country Status (32)

Country Link
US (1) US5762907A (cs)
EP (1) EP0462787B1 (cs)
JP (2) JP3636728B2 (cs)
KR (1) KR100219964B1 (cs)
CN (1) CN1033143C (cs)
AT (1) ATE123955T1 (cs)
AU (2) AU651112B2 (cs)
BR (2) BR9102579A (cs)
CA (1) CA2044812C (cs)
CS (1) CS184291A3 (cs)
CY (1) CY1891A (cs)
DE (1) DE69110554T2 (cs)
DK (1) DK0462787T3 (cs)
EG (1) EG19862A (cs)
ES (1) ES2073678T3 (cs)
FI (1) FI101044B (cs)
GR (1) GR3017430T3 (cs)
HK (1) HK80496A (cs)
HU (1) HU226897B1 (cs)
IE (1) IE71023B1 (cs)
IL (1) IL98536A (cs)
IS (1) IS1704B (cs)
MC (1) MC2260A1 (cs)
NO (1) NO302510B1 (cs)
NZ (1) NZ238547A (cs)
PH (1) PH30975A (cs)
PL (1) PL165699B1 (cs)
PT (1) PT97996B (cs)
RU (1) RU2095085C1 (cs)
SA (1) SA92120343B1 (cs)
SK (1) SK279598B6 (cs)
ZA (1) ZA914615B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5405601A (en) * 1993-07-02 1995-04-11 Mallinckrodt Medical Inc. Functionalized tripodal ligands for imaging applications
CN1065769C (zh) * 1997-07-03 2001-05-16 中国原子能科学研究院 一种放射性药物制剂的制备方法
CN1092962C (zh) * 1998-01-26 2002-10-23 贾伟 一种减轻骨及骨关节疾病疼痛的药物
RU2164420C2 (ru) * 1999-02-10 2001-03-27 Государственный научный центр Российской Федерации Физико-энергетический институт им. акад. А.И. Лейпунского Способ получения радиотерапевтического препарата
WO2000076556A2 (en) * 1999-06-11 2000-12-21 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
RU2162714C1 (ru) * 2000-06-20 2001-02-10 Государственный научный центр РФ - Институт биофизики Радиофармацевтическая композиция
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
RU2205030C2 (ru) * 2001-02-13 2003-05-27 Осминин Александр Георгиевич Средство для рентгенологического исследования
RU2182022C1 (ru) * 2001-05-24 2002-05-10 Российская медицинская академия последипломного образования МЗ РФ Способ лечения онкологических заболеваний щитовидной железы
RU2191033C1 (ru) * 2001-05-24 2002-10-20 Юминов Олег Аркадьевич Радиофармацевтический препарат "астат-211" для лечения онкологических заболеваний щитовидной железы
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
BR0215913A (pt) 2002-11-05 2005-08-09 Ion Beam Applic Sa Composição de radiofármacos rotulados com 18-f e processo para obtê-los
RU2297247C2 (ru) * 2005-06-20 2007-04-20 Государственное учреждение "Институт химии твердого тела" Уральского отделения Российской академии наук Средство для контрастирования при рентгенодиагностике (варианты)
CA2911414C (en) * 2013-05-13 2018-09-11 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
EP3054996B1 (en) 2013-10-07 2023-06-21 IGL Pharma, Inc. Process for preparing high purity therapeutic bone agents
KR102668112B1 (ko) 2014-12-04 2024-05-23 지이 헬쓰케어 리미티드 방사성 약제로부터의 아세트알데히드의 제거 방법
RU2593017C1 (ru) * 2015-04-23 2016-07-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения радиофармацевтического препарата "астат-211"
JP6880005B2 (ja) 2015-05-21 2021-06-02 アクティニウム ファーマシューティカルズ インコーポレイテッド 結合型モノクローナル抗体の注入投与
US11369700B2 (en) * 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
CA2987242C (en) * 2015-05-25 2023-10-10 Isotherapeutics Group, Llc Dotmp kit formulations for radioisotopes
RU2757258C1 (ru) * 2020-09-28 2021-10-12 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ) Способ получения радиофармацевтического препарата с галлием-68 для визуализации метастазов скелета методом пэт

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018883A (en) * 1975-03-10 1977-04-19 Nichols Institute For Endocrinology Thyroxine (T4) radioimmunoassay
CA1050425A (en) * 1975-06-26 1979-03-13 Mallinckrodt Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine
US4301140A (en) * 1979-12-14 1981-11-17 G. D. Searle & Co. Radiopharmaceutical method for monitoring kidneys
US4341755A (en) * 1980-07-15 1982-07-27 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4457602A (en) * 1981-04-20 1984-07-03 Olympus Optical Company Ltd. Multiple light emission control system utilizing electronic flashes
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
EP0164843B1 (en) * 1984-06-04 1991-06-19 The Dow Chemical Company Organic amine phosphonic acid complexes for the treatment of calcific tumors
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
GB8510726D0 (en) * 1985-04-26 1985-06-26 Amersham Int Plc Stabilised radio-labelled compounds
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
NZ222304A (en) * 1987-05-18 1990-10-26 Dow Chemical Co Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes
DE3854717T3 (de) * 1987-06-30 1999-04-15 Mallinckrodt, Inc. (N.D.Ges.Des Staates Delaware), St. Louis, Mo. Verfahren zur erhöhung der sicherheit von metall-ligandchelaten als röntgenstrahlen-kontrastmittel.
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4937333A (en) * 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes

Also Published As

Publication number Publication date
PL290717A1 (en) 1992-02-24
AU7847091A (en) 1991-12-19
CN1063615A (zh) 1992-08-19
IE912057A1 (en) 1991-12-18
CA2044812A1 (en) 1991-12-19
AU665911B2 (en) 1996-01-18
CS184291A3 (en) 1992-02-19
IS1704B (is) 1998-12-10
DK0462787T3 (da) 1995-10-30
ES2073678T3 (es) 1995-08-16
IL98536A0 (en) 1992-07-15
JP2002114712A (ja) 2002-04-16
EP0462787A1 (en) 1991-12-27
JP3636728B2 (ja) 2005-04-06
NO302510B1 (no) 1998-03-16
FI912933A0 (fi) 1991-06-17
HK80496A (en) 1996-05-17
BR9102579A (pt) 1992-01-21
EP0462787B1 (en) 1995-06-21
PT97996B (pt) 1998-11-30
NZ238547A (en) 1994-05-26
PH30975A (en) 1997-12-23
AU651112B2 (en) 1994-07-14
CN1033143C (zh) 1996-10-30
SK279598B6 (sk) 1999-01-11
HUT57994A (en) 1992-01-28
PT97996A (pt) 1992-03-31
EG19862A (en) 1996-06-30
SA92120343B1 (ar) 2004-01-25
ATE123955T1 (de) 1995-07-15
AU6455994A (en) 1994-08-04
NO912345L (no) 1991-12-19
IS3717A7 (is) 1991-12-19
RU2095085C1 (ru) 1997-11-10
BR1101169A (pt) 2000-08-08
FI912933L (fi) 1991-12-19
JPH04230224A (ja) 1992-08-19
HU226897B1 (en) 2010-01-28
HU912011D0 (en) 1991-12-30
DE69110554D1 (de) 1995-07-27
US5762907A (en) 1998-06-09
NO912345D0 (no) 1991-06-17
IL98536A (en) 1996-10-31
KR920000334A (ko) 1992-01-29
FI101044B (fi) 1998-04-15
CY1891A (en) 1996-08-30
KR100219964B1 (ko) 1999-09-01
IE71023B1 (en) 1997-01-15
CA2044812C (en) 2002-12-31
PL165699B1 (pl) 1995-01-31
ZA914615B (en) 1993-02-24
GR3017430T3 (en) 1995-12-31
DE69110554T2 (de) 1995-12-14

Similar Documents

Publication Publication Date Title
JP7650938B2 (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
EP0462787B1 (en) Radiopharmaceutical formulations, their method of administration and process of preparation
KR100671387B1 (ko) 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도
AU656915B2 (en) Stabilized therapeutic radiopharmaceutical complexes
JPS6216433A (ja) ラジオグラフィー用走査剤を調製するための水溶性物質
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
JP7805170B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN108290924A (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
EP0419387A1 (fr) Nouveaux dérivés hydrophiles, application au diagnostic et à la thérapeutique, kits diagnostiques ou thérapeutiques et réactifs immunologiques
AU2020349002A1 (en) Stable, concentrated radiopharmaceutical composition
JP3122319B2 (ja) 錫−１１７ｍ−含有放射性治療剤
JPS6126887B2 (cs)
JP2023518319A (ja) 放射性金属と複合するＤＺ－１－Ｌｙｓ－ＤＯＴＡコンジュゲート及び使用
JP7068222B2 (ja) 高純度治療用骨剤
Cheng et al. A Walker 256 tumor-induced osteogenic small animal model for the evaluation of [99mTc] diphosphonate radiopharmaceuticals
US11723992B2 (en) Method for extraction and purification of 68GA
AU654169B2 (en) Compositions and method for soft tissue tumors
JPH09169668A (ja) 治療剤